Pharmafile Logo
Pharmafocus logo
Advanced Search

cystic fibrosis

Showing 15 posts of 45 posts found.

vertex-headquarters

Vertex destroyed nearly 8,000 packs of Orkambi in 2018

March 28, 2019
Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis

Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …

News
vertex-headquarters

Vertex doubles Q4 profits, angering cystic fibrosis drug advocates in UK

February 11, 2019
Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma

Despite ongoing controversy surrounding the currently stalled negotiations between Vertex and the NHS to make its cystic fibrosis (CF) drug …

News
vertex-headquarters

Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission

January 22, 2019
Manufacturing and Production, Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma

Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 13, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten

It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Boehringer Ingelheim, Kite, Nordic Nanovector, Pfizer, Roche, Sanofi, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …

News
cystic_fibrosis_insider_interview

Transforming cystic fibrosis treatment

April 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …

Feature
upper-body-944557_960_720

Vertex “astonished” by NHS England’s response to CF drug

March 20, 2018
Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Vertex has been battling to have its treatment, Orkambi, approved in the UK since 2016, when it was first rejected …

News
cell-3089947_960_720

Vertex gets approval for combo-therapy in cystic fibrosis

February 13, 2018
Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

All eyes are on Vertex’s two Phase 3 trials into a triple therapy for cystic fibrosis (CF), in the meantime, …

News
heartbeat

Decade lifespan difference in Americans and Canadians with cystic fibrosis

March 15, 2017
Research and Development Canada, United States, cystic fibrosis

A new study has emerged looking into life expectancy of those with cystic fibrosis, funded by the US Cystic Fibrosis …

News
kalydeco

Vertex stumbles in Phase III cystic fibrosis trials

August 16, 2016
Manufacturing and Production, Research and Development Vertex, cystic fibrosis, phase III

Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in …

News
shutterstock_87495637

Orkambi deemed not suitable for NHS use

July 27, 2016
Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis

The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …

News

Synergy Vision MD appointed as trustee of the Cystic Fibrosis Trust

June 17, 2016
Medical Communications Synergy Vision, appointment, cystic fibrosis, cystic fibrosis trust, medical communications, medical communications agency

Managing director of Synergy Vision Ffyona Dawber has been appointed to the Cystic Fibrosis Trust’s board of trustees.  Her wealth …

News
Press release

Final Nice appraisal says no to cystic fibrosis drug, Orkambi

June 17, 2016
Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …

News

Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco

May 10, 2016
Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation

The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX).  SMC did not recommend …

News
nice

NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi

March 23, 2016
Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis

NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025